Bio News
Kunil Pharmaceutical’s pediatric and adolescent insomnia treatment Slenyto has expanded its indication to include sleep disorders associated with ADHD, following its indication for autism spectrum disorder. Sleep disorders affect 70% of children and adolescents with ADHD, while Slenyto maintains its efficacy for 8~10 hours with 3-mm mini-tablets and an extended-release technology. Kunil Pharmaceutical plans to improve access to treatment by holding academic symposia for specialists and other events.
BIOBOOK TEAM
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
